首页> 美国卫生研究院文献>Drug Design Development and Therapy >Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature
【2h】

Development of acquired factor V inhibitor after treatment with ceftazidime: a case report and review of the literature

机译:头孢他啶治疗后获得性V因子抑制剂的开发:一例报道并文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report the case of a 59-year-old Chinese man who showed an asymptomatic coagulation factor V deficiency pattern after second intravenous treatment with ceftazidime. Normal pooled plasma failed to correct the abnormalities in a mixing test, and the presence of factor V inhibitor was confirmed by the Bethesda method. The coagulopathy was not corrected by transfusion of fresh frozen plasma and prothrombin complex concentrate, but rather by treatment with prednisone and withdrawal of dubious drugs. The findings reported here should prompt clinicians to watch for drug-induced coagulation factor deficiency.
机译:我们报道了一例59岁的中国男子,在头孢他啶第二次静脉内治疗后显示无症状的凝血因子V缺乏症。正常的混合血浆未能纠正混合试验中的异常,并且通过Bethesda方法确认了V因子抑制剂的存在。凝血病不能通过输注新鲜的冷冻血浆和凝血酶原复合物浓缩物来纠正,而可以通过泼尼松治疗和停用可疑药物来纠正。此处报道的发现应促使临床医生注意药物引起的凝血因子缺乏症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号